• JHU-083: Unlocking Glutaminase Inhibition for Advanced Neuro

  2026-06-29

  Explore the scientific innovation of JHU-083, a 6-diazo-5-oxo-L-norleucine precursor, as a selective glutaminase antagonist for neurological disease models. This article uncovers its unique mechanism, practical considerations, and differentiates its value for glutaminase pathway research.

• Patient-Derived Gastric Cancer Assembloids Enhance Drug Resp

  2026-06-28

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids and stromal subpopulations, enabling more accurate preclinical drug response and resistance studies. The innovation lies in recapitulating tumor microenvironment complexity, revealing how stromal cells influence therapeutic sensitivity and resistance.

• IPA-3: Selective Pak1 Inhibition for Applied Kinase Research

  2026-06-27

  IPA-3, a selective inhibitor of Pak1 autophosphorylation, empowers researchers to dissect kinase signaling with unprecedented specificity and reproducibility. Learn how to optimize workflows, troubleshoot common issues, and leverage recent virology findings to maximize your experimental impact.

• Deferasirox Fe3+ Chelate: Optimizing Iron Overload Research

  2026-06-26

  Deferasirox Fe3+ chelate empowers advanced models of iron metabolism and lysosomal cell death, building on recent discoveries in nutrient sensing. This guide details robust protocols, troubleshooting strategies, and workflow optimizations for chronic iron overload and beta-thalassemia research, leveraging APExBIO's high-purity chelator.

• Thapsigargin: SERCA Pump Inhibitor for ER Stress & Apoptosis

  2026-06-26

  Thapsigargin, a gold-standard SERCA pump inhibitor, enables precise disruption of intracellular calcium homeostasis and controlled induction of endoplasmic reticulum (ER) stress. This article delivers actionable protocols, advanced use-cases, and troubleshooting strategies for researchers using Thapsigargin, drawing on validated workflows and recent breakthroughs in pulmonary and neurodegenerative models.

• IEM 1460: Precision AMPA Receptor Blocker for Neuroprotectio

  2026-06-25

  IEM 1460 stands out as a selective AMPA receptor blocker enabling reproducible, high-impact research on excitotoxicity and neuroprotection. Its robust performance and workflow adaptability empower neuroscience labs to dissect synaptic mechanisms and optimize neuroprotective strategies with confidence.

• Applied Cancer Research with JNJ-26854165 (Serdemetan): Prov

  2026-06-25

  JNJ-26854165 (Serdemetan) empowers researchers to dissect p53 pathway modulation, delivering measurable anti-proliferative and apoptosis-inducing effects in preclinical cancer models. This guide demystifies experimental setup, optimization, and troubleshooting, translating high-impact reference findings into actionable protocols for robust, reproducible results.

• I-BET151 (GSK1210151A): BET Inhibition for Cancer Workflows

  2026-06-24

  I-BET151 (GSK1210151A) unlocks precise modulation of epigenetic pathways in cancer biology, with well-validated protocols for apoptosis and cell cycle arrest assays. This article details advanced experimental workflows, comparative advantages, and troubleshooting strategies, enabling researchers to maximize the impact and reproducibility of BET inhibition studies.

• Valemetostat (DS-3201): Protocols for EZH2 Inhibition in Lym

  2026-06-23

  Valemetostat (DS-3201) stands at the forefront of epigenetic cancer therapy, offering researchers a potent and selective dual EZH1/EZH2 inhibitor to dissect chromatin regulation and enhance immunotherapy strategies. This guide details validated workflows, experimental optimizations, and troubleshooting approaches that maximize the translational impact of Valemetostat in lymphoma and adoptive T cell therapy research.

• Isradipine (Dynacirc) in Advanced Neuroprotection & Vascular

  2026-06-23

  Isradipine (Dynacirc) empowers researchers with selective L-type calcium channel blockade, enabling high-precision studies in neuroprotection and vascular smooth muscle relaxation. This article translates recent mechanistic findings and workflow insights into actionable protocols, troubleshooting advice, and comparative perspectives for cutting-edge calcium channel research.

• Tivozanib (AV-951): Applied Oncology Workflows & Optimizatio

  2026-06-22

  Tivozanib (AV-951) is redefining anti-angiogenic therapy research with unmatched selectivity for VEGFRs and robust performance in renal cell carcinoma models. This article delivers protocol-ready insights, advanced troubleshooting, and practical workflow enhancements for researchers seeking translational impact with APExBIO’s benchmark inhibitor.

• SIRT1 Activation by Resveratrol Restores Mitochondrial Bioge

  2026-06-22

  This study demonstrates that SIRT1 regulates mitochondrial damage in prion-challenged N2a cells by promoting mitochondrial biogenesis through the PGC-1α-TFAM pathway. Activation of SIRT1, specifically with resveratrol, effectively rescues mitochondrial function and reduces apoptosis, highlighting a mechanistic target for neuroprotection in prion diseases.

• DR5 Agonist Antibodies Induce PD-L1–Mediated Immune Evasion

  2026-06-21

  This study uncovers a previously unrecognized immunosuppressive mechanism whereby DR5 agonist antibodies stabilize PD-L1 on tumor cells, limiting immune infiltration and affecting the efficacy of apoptosis-based therapies in solid tumors. The findings illuminate a critical axis (DR5–ROCK1–PD-L1) and suggest combinatorial strategies could overcome immune resistance in cancer immunotherapy.

• DMXAA (Vadimezan): Workflow Innovation in Tumor Vascular Dis

  2026-06-20

  DMXAA (Vadimezan) enables precise, reproducible disruption of tumor vasculature and apoptotic induction in preclinical cancer models. This guide delivers actionable workflow enhancements, protocol parameters, and troubleshooting insights, uniquely informed by the latest mechanistic findings in endothelial signaling and STING axis modulation.

• Itraconazole (SKU B2104): Reliable Triazole Antifungal for C

  2026-06-19

  This article provides an evidence-driven, scenario-based guide for leveraging Itraconazole (SKU B2104) in cell viability, proliferation, and cytotoxicity assays targeting Candida species. It addresses key laboratory challenges and demonstrates how APExBIO’s formulation ensures reproducibility, sensitivity, and compatibility with advanced workflows.

450 records 13/30 page Previous Next First page 上5页 1112131415 下5页 Last page